Navigation Links
Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus
Date:9/22/2010

d acceptance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA). In addition to the United States, the Phase 2a clinical trials will be conducted in the Netherlands, Germany, Poland, Romania, and Slovakia.

The World Health Organization estimates about 3% of the world's population has been infected with HCV and that some 170 million are chronic carriers at risk of developing liver cirrhosis and/or liver cancer(2). Approximately 3-4 million Americans are chronically infected with an estimated 40,000 new infections per year(1). In Europe, there are about 4 million carriers(2). The current standard of care, pegylated interferon in combination with ribavirin, is effective in only about 50% of those treated(1).

Developed using Santaris Pharma A/S proprietary Locked Nucleic Acid (LNA) Drug Platform, miravirsen is a specific inhibitor of miR-122, a liver specific microRNA that the Hepatitis C virus requires for replication. Miravirsen is designed to recognize and sequester miR-122, making it unavailable to the Hepatitis C virus. As a result, the replication of the virus is effectively inhibited and the level of Hepatitis C virus is reduced.

"Advancing miravirsen, the first microRNA-targeted drug to enter clinical trials, into Phase 2 studies in patients with Hepatitis C demonstrates Santaris Pharma A/S leadership in developing RNA-targeted medicines," said Arthur A. Levin, Ph.D., Vice President, Chief Development Officer and President, US Operations. "Receiving IND acceptance from the FDA to conduct the first clinical trials with a microRNA-targeted drug in the United States brings Santaris Pharma A/S one step closer to potentially providing a growing number of patients chronically infected with HCV with a more effective and better tolerated treatment option."

The LNA Drug Platform is the only technology with both mRNA and microRNA targeted drugs in clinical trials, reinforcing the broad utility of
'/>"/>

SOURCE Santaris Pharma A/S
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Santaris Pharma A/S Advances RNA-Targeted Drug Development Candidate Against PCSK9, an Important New Target for the Treatment of High Cholesterol
2. New Collaborations and Breakthrough Advancements in RNA-Based Drug Development Programs Lead Santaris Pharma A/S to Establish US Operations
3. Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform
4. Santaris Pharma A/S Forms Strategic Alliance With Shire plc to Develop RNA-Based Medicines for the Treatment of Rare Genetic Disorders
5. Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
6. Santaris Pharma Director Appointed Adjunct Professor in RNA Biology at the University of Aalborg, Denmark
7. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
8. TOPICA Pharmaceuticals Announces Sublicensing Agreement for Tinea Indication
9. Keryx Biopharmaceuticals to Present at the UBS 2010 Global Life Sciences Conference
10. Helix BioPharma Approved for NYSE Amex Listing
11. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Colo. , May 23, 2013 Venaxis, ... diagnostic company focused on obtaining FDA clearance and commercializing ... today announced the pricing of an underwritten public offering ... warrants to purchase 3,500,000 shares of its common stock ... a combined public offering price of $1.25 per share ...
(Date:5/23/2013)... PuraMed BioScience ® , Inc., (OTCBB: ... (OTC) medicinal and healthcare products, announced that Ludlow ... based on low market capitalization valuation. ... Product to Treat Migraine Headaches , Clinical ... , Currently Available Nationwide at Walgreen,s and ...
(Date:5/23/2013)... , May 23, 2013  Saddleback Memorial Medical ... recently became the first hospital on the West Coast ... This new surgical option provides women with a state-of-the-art, ... Marc Winter , M.D., a highly ... surgeon and medical director of minimally invasive surgery at ...
(Date:5/23/2013)... 2013 Northwest Biotherapeutics (NASDAQ: NWBO ... personalized immune therapies for solid tumor cancers, announced ... year,s American Society Of Clinical Oncology (ASCO) meeting in ... role in immune therapy.  (Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO ... the pre-eminent conference focused on clinical treatment of cancer, ...
Breaking Biology Technology:Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3
... Diamyd Medical AB,( http://www.omxgroup.com, ticker: DIAM B; ... Medical permission to start a Phase III,clinical study in ... therapeutic,diabetes vaccine Diamyd(R)., (Logo: http://www.newscom.com/cgi-bin/prnh/20080314/297194 ), ... to be able to offer this,promising drug to our ...
... ROCKVILLE, Md., March 14 Human Genome,Sciences, Inc. (Nasdaq: ... the,Cowen and Company 28th Annual Health Care Conference will ... ., (Logo: http://www.newscom.com/cgi-bin/prnh/20010612/HGSLOGO ), A ... present,a corporate overview on Wednesday, March 19, 2008 from ...
... March 14 Kosan Biosciences,Incorporated (Nasdaq: KOSN ... Vice President and Chief Financial Officer, will present ... Conference in Boston at the,Boston Marriott Copley Place ... Time. A live webcast of the presentation can ...
Cached Biology Technology:Diamyd Gets Authorization to Begin Phase III Study in the US 2Kosan Biosciences to Present at the Cowen and Company 28th Annual Health Care Conference 2
(Date:5/24/2013)... the world,s largest and fastest growing open-access publishers, today ... in Physics . , A broad scope journal covering ... an open-science and interactive web platform for the research ... , Frontiers, real-time and interactive peer-review enables fast, ... types. With an average of three months from submission ...
(Date:5/24/2013)... have focused among other factors on drugs that ... the accumulation of A-beta that causes the known plaques in ... of A-beta is APP. Alessia Soldano and Bassem Hassan (VIB/KU ... the fruit-fly version of APP in the brain ... "We have discovered that APPL ensures that brain cells form ...
(Date:5/23/2013)... 284 million tons of cargo, transit the Panama Canal each ... the Panama Canal Authority. Each time a ship passes through, ... Gatun Lake, which is also a source of water for ... However, the advent of very large "super" cargo ships, now ... demanded change. The Panama Canal is being expanded to create ...
Breaking Biology News(10 mins):Frontiers launches new open-access journal in physics 2Frontiers launches new open-access journal in physics 3A new strategy required in the search for Alzheimer's drugs? 2Reforestation study shows trade-offs between water, carbon and timber 2Reforestation study shows trade-offs between water, carbon and timber 3
... the human genome sequence annotation, high-throughput cloning methodologies, ... of Proteomics lead by Leonardo Brizuela (Harvard Medical ... mined public databases to collect the sequence information ... built a gene repository for this gene class. ...
... sake of five others may be the way to go ... building, but a Penn State Erie biologist is monitoring the ... animals and insects. , "I am currently doing research in ... wetlands to replace all the ones that were destroyed by ...
... suspected that fertilizer runoff from big farms can trigger ... ecosystems and even producing "dead zones" in the sea. ... the first direct evidence linking large-scale coastal farming to ... the March 10 issue of the journal Nature, the ...
Cached Biology News:Road salt affects mitigation wetlands 2Oceans more vulnerable to agricultural runoff than previously thought, study finds 2Oceans more vulnerable to agricultural runoff than previously thought, study finds 3Oceans more vulnerable to agricultural runoff than previously thought, study finds 4
... for determination of baculovirus titers in just 2448 ... methods. Classical determination of baculovirus titer has relied ... Kit takes advantage of the appearance of detectable ... surface as early as 824 hours post-infection. Detection ...
...
... Silica Bead Kit has been designed for recovery of ... Features Ultra fast protocol: DNA ... silica beads are easy to resuspend Bead uniformity ... pure DNA (suitable for PCR) DNA is eluted ...
... BAS-2500 is ideal for ... Biology (1D electrophoresis, 2D ... Macroarrays); Pharmacokinetics & Toxicology ... layer chromatography); Physical and ...
Biology Products: